BUENA, N.J.--(BUSINESS WIRE)--March 28, 2005--IGI, INC. (AMEX: IG - News) is scheduled to report financial results for the fourth quarter and year end 2004 on Thursday, March 31, 2005, prior to the market open.
IGI will hold a conference call at 10:00 AM ET on Thursday, March 31, 2005 to discuss its financial results and continuing business plans. Interested parties are invited to listen to the call live over the Internet at www.companyboardroom.com or by dialing 1-800-659-1966, passcode 38030494. International participants should call 1-617-614-2711using the same passcode as above. For interested parties unable to join the call, a replay will be available until April 7, 2005, by dialing 1-888-286-8010, passcode 23880440.
IGI is a company committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs. IGI offers the patented NovasomeŽ nano-vesicular, transdermal delivery technology which contributes value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption, controlled and sustained release as well as improved stability and greater ease of formulation. IGI has licensed NovasomeŽ nano-vesicular delivery technology to leading global dermatological and skin care companies including Johnson & Johnson Consumer Products, Inc., Estee Lauder Corporation, Chattem Inc., Genesis Pharmaceutical, Inc. and Apollo Pharmaceutical, Inc., and recently sub-licensed the rights to obtain FDA approval for and market IGI's PTH (1-34) compound using NovasomeŽ nano-vesicular delivery technology for psoriasis, which is slated for Phase II clinical trials, to Tarpan Pharmaceuticals, Inc. IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy.
This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.
Contact: IGI, Inc. Frank Gerardi, 856-697-1441 ext. 102 GERARDI700@aol.com